Semin Cancer Biol. 2017 Nov 26. pii: S1044-579X(17)30097-4. doi: 10.1016/j.semcancer.2017.11.019. [Epub ahead of print]
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
EGFR mutations; Fine needle aspiration (FNA) biopsy; Non-small cell lung carcinoma (NSCLC); PD-L1 immunotherapy; Targeted therapy